CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1

FUJITA Ken-ichi; FUJITA Ken-ichi; YAMAMOTO Wataru; ENDO Shoji; ENDO Hisashi; NAGASHIMA Fumio; ICHIKAWA Wataru; TANAKA Ryuhei; MIYA Toshimichi; ARAKI Kazuhiro; KODAMA Keiji; SUNAKAWA Yu; NARABAYASHI Masaru; MIWA Keisuke; ANDO Yuichi; AKIYAMA Yuko; AKIYAMA Yuko; KAWARA Kaori; KAMATAKI Tetsuya; SASAKI Yasutsuna; SASAKI Yasutsuna

Art

J-GLOBAL ID：200902298109940713 Reference number：08A0426920

CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1

S-1を投与されている日本人癌患者においてCYP2A6と5-クロロ-2,4-ジヒドロキシピリジンの血漿レベルはそれぞれテガフールと5-フルオロウラシルの薬物動態学的変動性の決定因子である

Publisher site Copy service {{ this.onShowCLink("http://jdream3.com/copy/?sid=JGLOBAL&noSystem=1&documentNoArray=08A0426920&COPY=1") }}
Access JDreamⅢ for advanced search and analysis. {{ this.onShowJLink("http://jdream3.com/lp/jglobal/index.html?docNo=08A0426920&from=J-GLOBAL&jstjournalNo=W1423A") }}

Author (21)： , , , , , , , , , , , , , , , , , , , ,
Material：
Volume： 99 Issue： 5 Page： 1049-1054 Publication year： May. 2008
JST Material Number： W1423A ISSN： 1347-9032 Document type： Article
Article type：原著論文 Country of issue： Australia (AUS) Language： ENGLISH (EN)

,...
,...

To see more with JDream III (charged). {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=08A0426920&from=J-GLOBAL&jstjournalNo=W1423A") }}

Basic biopharmacy , Genetic variation

, , ,

Reference (33)：

OHTSU, A. Disparities in gastric cancer chemotherapy between the East and West. J Clin Oncol. 2006, 24, 2188-2196
BOKU, N. Randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG9912). J Clin Oncol. 2007, 25, 965S
NARAHARA, H. Randomized phase III study of S-1 alone versus S-1 +cisplatin in the treatment for advanced gastric cancer (The SPIRITS trial) SPIRITS. S-1 plus cisplatin vs S-1 in RCT in the treatment for stomach cancer. J Clin Oncol. 2007, 25, 201S
SHIRASAKA, T. Antitumor activity of 1M tegafur-0.4M 5-chloro-2, 4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res. 1991, 56, 2602-2606
IKEDA, K. Bioactivation of tegafur to 5-fluorouracil is catalyzed by cytochrome P450 2A6 in human liver microsomes in vitro. Clin Cancer Res. 2000, 6, 4409-4415

ｍore...

, , , , , , , ,

Return to Previous Page